echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > The price of Zhengda Tianqing dasatinib is only 1 / 8 of the original research drug, and the import substitution is also expected to accelerate

    The price of Zhengda Tianqing dasatinib is only 1 / 8 of the original research drug, and the import substitution is also expected to accelerate

    • Last Update: 2014-07-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    In April and June, Zhengda Tianqing dashatini was successively incorporated into the record procurement of Shandong and Hubei Province

    The price of 50mg specification was 70 yuan / tablet and 20mg specification was 35 yuan / tablet, while the price of 50mg and 20mg of original research manufacturer Bristol Myers Squibb was 526 yuan / tablet and 260 yuan / tablet, with a staggering price difference

    It is worth noting that in Hubei's record procurement, both Zhengda Tianqing and Bristol Myers Squibb have been selected, but the price gap is obvious; while Shandong market has seen signs of import substitution, and Zhengda Tianqing dominates the whole market

    Dasatinib is a specific drug for the treatment of chronic myeloid leukemia

    It was listed by Bristol Myers Squibb in 2006 and first imported to China in 2011

    At present, it is only sold in Hainan, Yunnan, Hubei, Jiangsu and Jilin provinces

    In China, only Zhengda Tianqing and Shuanglu pharmaceutical have declared according to category 3.1, and other manufacturers have declared production according to category 6 generic drugs since 2013

    Zhengda Tianqing started the project development of this product in 2009

    It took 4 years of unremitting efforts to explore new process routes, and finally successfully developed dasatinib

    In the process of research and development, scientific researchers strictly control all impurities according to the technical requirements of the European drug review agency (EMEA), so that the total impurity content of "enishu" is less than 0.2%, and the single impurity content is about 0.05%

    The purity of Zhengda Tianqing "yinishu" is more than 99.8%, the stability is good, and the quality is not inferior to the imported preparation

    At present, Shuanglu Pharmaceutical Co., Ltd

    is still in the stage of "review", and the company expects to be approved for production by the end of the year

    Before that, the company also made its first attempt

    Shuanglu pharmaceutical has repeatedly questioned Zhengda Tianqing's patent for the drug

    It has pointed out that the patent protection period of dasatinib is about 10 years, and other enterprises' listing and sales within the patent period constitute infringement

    Many foreign new drugs have obtained the production approval for the imitations of many manufacturers during the patent period, "but all enterprises dare to go on sale only the next day after the patent expires"

    However, Zhengda Tianqing has entered the market by virtue of its first mover advantage and patent evasion

    Insiders pointed out that provincial bidding could be opened in the second half of the year

    In the bidding environment of "two standards in one", Zhengda Tianqing dashatini will take advantage of its first imitative qualification and pricing advantage to take the lead in layout in each province

    After being approved, the marketing difficulty of Shuanglu pharmaceutical will be greatly increased Add

    Dasatinib, formerly known as BMS-354825, is a cancer treatment drug produced by Bristol Myers Squibb and sold in the name of "sprycel"

    In 2012, Zhengda Tianqing evaluated the bioequivalence of "enisu" with "starxay" produced by Bristol Myers Squibb as the reference preparation

    The results showed that the pharmacokinetic parameters of the two preparations were the same, and the bioavailability of "yinishu" relative to "shidasai" was 115.8%; the product of Zhengda Tianqing was bioequivalent with the imported preparation, and the safety indexes were the same

    In the course of CML treatment, a considerable number of patients are resistant to imatinib, and with the increase of the number of years of treatment and the aggravation of the disease, the probability of drug resistance also increases

    Dasatinib is the life-saving drug for these patients

    Dasatinib was approved by FDA on June 28, 2006 and entered China in September 2011

    However, at present, dasatinib is only sold as an imported preparation, which is expensive and not affordable for ordinary families

    The high drug price makes the patients with imatinib resistance unable to pay can only watch the disease worsen

    Domestic patients have been looking forward to the listing of domestic dasatinib for a long time

    The approval of Zhengda Tianqing dasatinib to market will fill the gap of this product in China, break the current situation of high price of imported drugs, reduce the cost of clinical treatment, and open a life door for patients with leukemia who are intolerant to imatinib

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.